
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx achieved breakeven on operating profit in the third quarter of 2024, with expectations for continued improvement in operating margins as sales increase and R&D spending stabilizes, supported by significant growth in global product net sales, which reached $737 million in the fourth quarter of 2024, reflecting a 29% quarter-over-quarter and 97% year-over-year increase. The company's strong revenue growth is attributed to sustained demand for its lead product, Vyvgart, which exhibits profound efficacy and a favorable safety profile, solidifying its position as the first branded biologic for generalized myasthenia gravis (gMG). Furthermore, Argenx's commitment to innovation is underscored by its robust pipeline and strategic R&D investment, which targets future growth in various rare autoimmune diseases, with projected revenue from Vyvgart in gMG, CIDP, and ITP expected to reach $3.2 billion by 2025.
Bears say
Argenx has reported a year-over-year decrease in R&D expenses, which fell 3.0% to $297.2 million, slightly exceeding analysts' estimates but indicating potential financial challenges in maintaining innovation. The company faces substantial risks, including slower-than-expected sales growth for its lead product, Vyvgart, along with significant competitive pressure and the potential for setbacks in ongoing developmental programs. Additionally, any clinical or regulatory issues could adversely impact the stock price, and a historic precedent exists in the biopharmaceutical sector where companies, like BIIB, have experienced revenue decline due to competition and loss of exclusivity, raising concerns for Argenx's future financial performance.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares